key: cord-0950071-yp476zp3 authors: Eroğlu, İmdat; Eroğlu, Burcu Çelik; Güven, Gülay Sain title: Altered Tryptophan Absorption And Metabolism Could Underlie Long-term Symptoms In Covid-19 Survivors date: 2021-05-01 journal: Nutrition DOI: 10.1016/j.nut.2021.111308 sha: 18952f1d3b792163795c0d94b1f1f3050ea33211 doc_id: 950071 cord_uid: yp476zp3 The global pandemic of COVID-19 has been lasting for more than one year and there is little known about the long-term health effects of the disease. Long-COVID is a new term that is used to describe the enduring symptoms of COVID-19 survivors. Huang et al. reported that fatigue, muscle weakness, sleep disturbances, anxiety, and depression were the most common complaints in COVID-19 survivors after 6 months of the infection. A recent meta-analysis showed that 80% of COVID-19 survivors have developed at least one long-term symptom and the most common five were fatigue, headache, attention deficit disorder, hair loss, and dyspnea. In this paper, we discuss the hypothesis that altered tryptophan absorption and metabolism could be the main contributor to the long-term symptoms in COVID-19 survivors.  COVID-19 causes long-term symptoms for example; fatigue, depression, sleep disturbances, muscle weakness  COVID-19 causes altered metabolism of tryptophan in favor of kynurenine pathway and disturbed tryptophan absorption due to altered expression of intestinal ACE-2  Both increased kynurenine pathway and decreased absoprtion of trytophan could be a main contributor to long-term symptoms of COVID-19 survivors. we discuss the hypothesis that altered tryptophan absorption and metabolism could be the main contributor to the long-term symptoms in COVID-19 survivors. L-Tryptophan (Try) is an essential amino acid that is obtained primarily through dietary intake in humans. Besides being a building block for protein synthesis, it also serves as a precursor for some important biological molecules such as serotonin, melatonin, and tryptamine [4] . While only about %5 of the free Try is used in the production of protein, neurotransmitters, and neuromodulators, the kynurenine (Kyn) pathway (KP) degrade more than %95 of free tryptophan (see. Figure 1 .). The conversion of Try to N-formylkynurenine is the rate-limiting step in the KP, which is catalyzed by three enzymes; indoleamine-2, 3 dioxygenase 1 (IDO-1), IDO-2 and tryptophane-2, 3 dioxygenase (TDO). Although TDO is found primarily in the liver, IDO is the main extrahepatic enzyme of the KP and can be found in various cells including macrophages. Kynurenines (metabolites generated in KP) have some central roles on inflammatory, immunological responses and also been linked to psychiatric disorders such as depression [5, 6] . It is known that IDO-1 is the primarily extrahepatic enzyme of the KP and can be induced by several proinflammatory cytokines such as tumor-necrosis factor-alpha (TNF-a), interferons (IFNs), and prostaglandins. IFN-gamma is the most potent stimulator of the IDO enzymatic activity. That is why IDO activity increases in case of inflammation like chronic inflammatory diseases, infections, and cancers [7] . A number of studies suggested that IDO-1 activation is essential for the inhibition of intracellular pathogens and tumor cells. The activated KP in IDOcompetent cells reduces inflammation and promotes long-term immune tolerance by inducing the proliferation of regulatory T cells. Along with the immunoregulation effect, IDO also works as an intracellular pathogen repressor by removing environmental tryptophan, which is required for replication of the microorganism during infection [8] [9] [10] . Several studies looked into changes in the tryptophan metabolism in SARS-CoV-2 infected patients and found augmented activation of KP. Thomas The Kyn:Try ratio was also higher in patients with severe lymphopenia which is an ominous prognostic predictor in COVID-19, and in males who are thought to be more vulnerable to infection [9] . Altered tryptophan metabolism in acute COVID-19 infection was also supported by several other studies [12, 13] . It is still unclear if KP activation is a defense mechanism or a mechanism that causes infection to flare up by inducing immune tolerance. While several studies have indicated that acute COVID-19 infection causes increased KP activation, there is no evidence of long-term effects of disturbed tryptophan metabolism in these patients. As discussed below, kynurenines could underlie long-COVID symptoms. As discussed before, the most commonly seen long-term symptoms in COVID-19 survivors were depression, fatigue, sleep disturbances, attention disorders, anxiety, muscle weakness, and dyspnea. When taken together, KP activation may also contribute these symptoms. The "kynurenine shunt" refers to the increased degradation of tryptophan towards kynurenine and away from serotonin production [14] . Increased IDO activity has been related to depression in studies, owing to both serotonin depletion and neurotoxic effects of KP metabolites [15] . Fatigue, the most common long-term symptom in COVID-19 survivors, is divided into central and peripheric fatigue, with central fatigue causing complex weakness and making recovery difficult [16] . Several studies revealed that increased metabolites of the KP in the brain trigger central fatigue and memory issues by inducing neurotoxicity [17] [18] [19] [20] . The long-term symptoms could be related to the kynurenine shunt seen in COVID-19 infection. While there has been evidence of increased KP activation in acute COVID-19, there is no evidence in long-term COVID-19 survivors. Studies in this area can aid in our understanding of the pathophysiology underlying COVID-19's long-term symptoms. COVID-19 has the ability to cause Try malabsorption in addition to disrupting Try metabolism. It is known that SARS-CoV2 uses ACE2 as a receptor and ACE2 expression is abundant in the intestines. When SARS-CoV2 infects the intestines, it disrupts the expression of ACE2 in the gastrointestinal system [21] . ACE2 is required for the expression of intestinal B0AT1, which is a neutral amino acid transporter in the intestinal lumen. Therefore, there could be a relatively neutral amino acid malabsorption in case of diminished ACE2 expression in the intestines. It has been evidenced that plasma tryptophan levels significantly decline in ACE2-lacking mice [22] . L-tryptophan is the main precursor of serotonin and other neurotransmitters which have a key role in the pathogenesis of depression and anxiety. Previous studies have shown that brain serotonin levels are low in ACE2-deficient mice [23] . Acute tryptophan depletion in rodents decreased tryptophan levels by up to %70 in the brain resulting in lower central serotonin levels in the brain and caused inhibition of serotonin synthesis in humans. Acute tryptophan depletion has also been linked to mood disturbances especially in people who are prone to depression [24] [25] [26] . Melatonin, one of the end-products of the Try, has plays an important role in sleep control as well as immune response. Try deficiency has been shown to reduce rapid eye movement (REM) latency and lengthen REM sleep [27, 28] . On the other hand, tryptophan also plays a major role in skeletal muscle mass regulation. Ninomiya et al. found that skeletal muscle mass in lymphoma patients was closely associated with the serum tryptophan levels. Moreover, they also revealed that there was a reversible muscle loss in mice fed with a tryptophan-deficient diet [29] . In addition to lung damage, COVID-19 patients' long-term dyspnea may be caused by weakness of the diaphragm muscle due to relative tryptophan deficiency. In conclusion, COVID-19 infection causes long-term dysregulation of Try absorption from the intestines due to ACE2 imbalance in the gastrointestinal system. Furthermore, Try metabolism is also disturbed in favor of KP. Low serum and muscle tryptophan levels, as well as elevated kynurenine levels, may be to blame for COVID-19's most common long-term symptoms such as depression, sleep disturbances, fatigue, and muscle weakness which are similar to the symptoms of tryptophan-deficient patients. It is unknown that whether the severity of the gastrointestinal symptoms during acute infection or tryptophan supplementation has an influence on the longterm health effects of COVID-19. We strongly believe that COVID-19-related alteration in Try absorption and metabolism could be the underlying pathophysiology of Long-COVID symptoms. COVID-19 survivors should be evaluated for nutritional status and tryptophan and tryptophan's metabolite levels in long term. Attributes and predictors of long COVID 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. Available at SSRN 3769978 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health Kynurenine Pathway Metabolites in Humans: Disease and Healthy States Targeting a metabolic pathway to fight the flu. The FEBS journal Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study Indoleamine 2, 3 dioxygenase and metabolic control of immune responses COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2. International journal of molecular sciences Serum neopterin levels in relation to mild and severe COVID-19 Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies Potential Role of Neuroactive Tryptophan Metabolites in Central Fatigue: Establishment of the Fatigue Circuit Role of kynurenines in the central and peripherial nervous systems Essential role of excessive tryptophan and its neurometabolites in fatigue Presynaptic kynurenate-sensitive receptors inhibit glutamate release The astrocyte-derived α7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities-Role of gut microbiota dysbiosis ACE2-From the renin-angiotensin system to gut microbiota and malnutrition. Microbes and infection Depletion of angiotensin-converting enzyme 2 reduces brain serotonin and impairs the running-induced neurogenic response. Cellular and molecular life sciences Acute tryptophan and serotonin depletion using an optimized tryptophan-free protein-carbohydrate mixture in the adult rat Differences between males and females in rates of serotonin synthesis in human brain Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood Possible role of tryptophan and melatonin in COVID-19 Low levels of serum tryptophan underlie skeletal muscle atrophy